Zolbetuximab for previously untreated advanced gastric or gastro-oesophageal junction adenocarcinoma

Zolbetuximab is in clinical development for the treatment of previously untreated metastatic or
locally advanced unresectable gastric cancer (GC) or gastroesophageal junction adenocarcinoma
(GEJC) that is HER2-negative and CLDN18.2-positive. GC and GEJC are types of cancers that
form in the inner lining of the stomach or where the stomach and the oesophagus meet. Advanced
unresectable GC is cancer that started in the stomach and has spread to another part of the body
and cannot be removed through surgery. CLDN18.2 is a protein found in the glands lining the
inside of the stomach, where it helps the gastric cells to stick to each other. In patients with GC
or GEJC, CLDN18.2 is much more widespread and is involved in the survival and spread of the
cancer cells. CLDN18.2 represents a potential drug target for the treatment GC or GEJC.